These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32285259)

  • 21. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible.
    Palsson O; Love TJ; Gunnarsdottir AI; Gunnarsson PS; Runarsdottir EE; Krogh NS; Gudbjornsson B
    RMD Open; 2019; 5(2):e000984. PubMed ID: 31413869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.
    Almirall M; Rodriguez J; Mateo L; Carrascosa JM; Notario J; Gallardo F
    Clin Rheumatol; 2017 Feb; 36(2):439-443. PubMed ID: 27817126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.
    Asahina A; Umezawa Y; Yanaba K; Nakagawa H
    J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN Study.
    Wendler J; Damann N; Röcken M; Teicher V; Schuier M; Hamann F; Schwenke H; Sieburg M; Behrens F
    Rheumatol Ther; 2022 Oct; 9(5):1435-1450. PubMed ID: 36066750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.
    Ramiro S; Smolen JS; Landewé R; van der Heijde D; Dougados M; Emery P; de Wit M; Cutolo M; Oliver S; Gossec L
    Ann Rheum Dis; 2016 Mar; 75(3):490-8. PubMed ID: 26660203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
    J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
    [No Abstract]   [Full Text] [Related]  

  • 27. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
    Bayaraa B; Imafuku S
    J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
    O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
    Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
    Siebert S; Sweet K; Dasgupta B; Campbell K; McInnes IB; Loza MJ
    Arthritis Rheumatol; 2019 Oct; 71(10):1660-1669. PubMed ID: 31070869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.
    Korotaeva TV; Loginova EY; Getiya TS; Nasonov EL
    Ter Arkh; 2018 May; 90(5):22-29. PubMed ID: 30701886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis.
    Appani SK; Devarasetti PK; Irlapati RVP; Rajasekhar L
    Rheumatology (Oxford); 2019 May; 58(5):869-873. PubMed ID: 30590763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.
    Feletar M; Brockbank JE; Schentag CT; Lapp V; Gladman DD
    Ann Rheum Dis; 2004 Feb; 63(2):156-61. PubMed ID: 14722204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
    Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
    Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
    J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of combining biologics with methotrexate for treatment of psoriatic arthritis-questions remain].
    Dauth S; Köhm M; Rossmanith T; Herrmann E; Lehn A; Burkhardt H; Behrens F
    Z Rheumatol; 2018 Nov; 77(9):808-814. PubMed ID: 30203153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
    Thibodaux RJ; Triche MW; Espinoza LR
    Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.